Table 3.

Individual estimated absorbed doses in kidneys, liver, parotid and submandibular glands determined for [¹⁶¹Tb]Tb-PSMA-617 vs. [¹⁷⁷Lu]Lu-PSMA-617

		Absorbed dose (mGy/MBq)
		[161Tb]Tb-PSMA-617				[177Lu]Lu-PSMA-617
Patient	Pre-treatment	Kidneys	Liver	Parotid gland	Subman. gland	Kidneys	Liver	Parotid gland	Subman. Gland
patient 1	N, C, L, R	0.638	0.290	0.793	0.718	0.666	0.199	0.398	0.309
patient 2	N, C, L, A, R	0.537	0.167	0.312	0.223	0.492	0.138	0.150	0.190
patient 3	N, C, L, A, R	0.942	0.196	0.197	0.205	0.906	0.069	0.146	0.112
patient 4	N, C, L, A, R	0.483	0.090	0.338	0.446	0.674	0.125	0.703	0.664
patient 5	N, C, L	0.284	0.051	0.227	0.194	0.252	0.037	0.217	0.178
patient 6	N, C, L, A	0.974	0.093	0.338	0.446	0.278	0.049	0.387	0.259
mean ± SD		0.643 ± 0.247	0.148 ± 0.080	0.367 ± 0.198	0.372 ± 0.188	0.545 ± 0.231	0.103 ± 0.057	0.333 ± 0.194	0.285 ± 0.180

A, [²²⁵Ac]Ac-PSMA-617 RLT; C, chemotherapy; N, novel androgen axis drugs; L, [¹⁷⁷Lu]Lu-PSMA-617 RLT; R, [²²³Ra]Ra-dichloride; SD, standard deviation